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ORIGINAL CONTRIBUTIONS 
Aging and Human Hormonal and Pressor 
Responsiveness to Angiotensin II Infusion 
With Simultaneous Measurement of 
Exogenous and Endogenous Angiotensin II 
Joseph Duggan, Juerg Nussberger, S. Kilfeather, and Κ O'Malley 
A decline in the function of the renin angiotensin 
aldosterone system may induce adaptive changes in 
response to angiotensin II (ANG II) with age. We 
have examined platelet ANG II receptor density, 
blood pressure and aldosterone responses to ANG 
II [Asn 1, Val 5-ANG II] (Hypertensin, Ciba Geigy, 
Horsham, Sussex, England) infusion in 8 young, 24 
to 30 years, and 8 older, 54 to 65 years, healthy vol­
unteers. To measure circulating ANG II, we estab­
lished a new method for specific and simultaneous 
measurement of exogenous [Asn^Val 5] (Hyperten-
sin) and endogenous [Aspx,Ile5] ANG II in plasma 
by using isocratic HPLC and radioimmunoassays 
with cross-reacting antibodies and compared re­
sults with immunoreactive ANG II which was mea­
sured conventionally using monoclonal antibodies. 
Baseline endogenous ANG II (AspSlle^ANG II) 
levels in venous plasma were marginally, but not 
significantly, lower in the old [mean (95% confi­
dence limits): 3.4 « 0 . 1 to 7.7) ν 3.7 (1.2 to 6.2), fmol/ 
mL] and during suppression by the Hypertensin in­
fusion appeared consistently, but not significantly, 
lower in the old [0.9 (0 to 3.1) ν 2.1 (0.6 to 3.7), after 3 
ng/kg/min], while the same infusion rate in young 
and old resulted in similar plasma Hypertensin 
levels. Baseline systolic blood pressure (SBP) was 
similar in both groups but the percentage increases 
in SBP at infusion rates of 1, 3.0, and 10 ng/kg/min 
were greater in the old than in the young (9.1 ν 2.8, 
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Ρ < .05; 16.3 ν 8.0, Ρ < .01; 30.4 ν 14.0%, Ρ < .001, re­
spectively). The increment in diastolic blood pres­
sure or mean arterial pressure during infusion did 
not differ significantly between the groups. Heart 
rate fell significantly during ANG II infusion in 
young (P < .05) but not old subjects. Basal plasma 
aldosterone was similar in both groups. However, 
the percentage increases in plasma aldosterone 
were greater in young than old at infusion rates of 
1.0, 3.0, and 10.0 ng/kg/min (94 ν - 5 ; 238 ν 28; 462 
ν 69%, all Ρ < .001). Platelet ANG II receptor den­
sity was elevated in the old [6.5 (1.9 to 11.1) ν 1.14 
(0.21 to 2.07), fmol/10 9 cells, Ρ < .01]. 
Our findings demonstrate that it is possible to 
measure specifically and simultaneously exogenous 
and endogenous ANG II in plasma during Hyper­
tensin infusion and that endogenous ANG II con­
centrations decrease with increasing levels of exog­
enous ANG II. During infusion, similar plasma 
Hypertensin levels were attained in both young 
and old, but systolic blood pressure responsiveness 
was increased in the old, while adrenal responsive­
ness was reduced. Am J Hypertens 1993;6:641-647 
K E Y W O R D S : Age, angiotensin II infusion, blood 
pressure, aldosterone, HPLC, radioimmunoassay, 
platelet angiotensin II receptor density, Asn^Val 5 -
angiotensin II (Hypertensin). 
The etiology of the age related rise of blood pres­sure in Western societies is not clear. Several hormonal systems involved in blood pressure regulation undergo changes with age, including 
the sympathetic,1 atrial natriuretic peptide,2'3 and the 
renin angiotensin aldosterone systems (RAAS). 4" 7 In 
© 1993 by the American Journal of Hypertension, Ltd. 0895-7061/'93/'$6.00 
642 DUGGAN ET AL AJH-AUGUST 1993-VOL 6, NO. 8 
particular, there is a decline in the function of the RAAS 
with age 4 " 7 with a well documented fall in both plasma 
renin activity (PRA) and aldosterone. Since PRA and 
ANG II correlate closely,8 it is conceivable that plasma 
ANG II would also decline with age and contribute to 
falling plasma aldosterone with age. A fall in plasma 
ANG II could also result in adaptive changes in receptor 
density or responsiveness in vascular smooth muscle or 
adrenal zona glomerulosa since circulating plasma ANG 
II regulates its vascular smooth muscle, platelet, and 
adrenal zona glomerulosa receptors. 9 - 1 2 In particular, 
sodium loading which results in a fall in plasma ANG II 
is associated with an increase in both rat vascular 
smooth muscle 1 1 and human platelet12 ANG II receptor 
density, but a decrease in adrenal zona glomerulosa 
ANG II receptor density in the rat . 9 , 1 0 Furthermore, 
there is some evidence to suggest that responses to ANG 
II infusion in humans are altered with aging which re-
sults in increased blood pressure but reduced aldoster-
one responses to ANG II infusion. 1 3 , 1 4 There appears, 
therefore, to be an apparent similarity between receptor 
density changes under conditions of low circulating 
ANG II and reported changes in pressor and aldoster-
one responses to ANG II infusion with aging in humans. 
The purpose of the present study was to investigate the 
effect of age on blood pressure, heart rate, plasma en-
dogenous ANG II [Asp1,Ile5-ANG II] and aldosterone 
responses to ANG II [Asn1,Val5-ANG II] (Hypertensin 
Ciba Geigy, Horsham, Sussex, England) infusion in 
normal human subjects and also to measure their plate-
let ANG II receptor density. Conventional ANG II mea-
surement provides only immunoreactive ANG II (ir-
ANG II) levels and cannot distinguish between 
exogenous and endogenous ANG II. We developed an 
HPLC-based method which allowed us to monitor 
simultaneously these two peptides by separate mea-
surement within the same plasma sample and to com-
pare these results with conventionally estimated ir-
ANG II concentrations. 
METHODS 
Subjects Eight young (age range 24 to 30 years; 1 fe-
male and 7 male) and eight older (54 to 65 years; 1 
female and 7 male) normotensive healthy subjects were 
studied. All subjects had a normal physical examina-
tion, hematological and biochemical screen, and elec-
trocardiogram and none were taking medication. The 
study was conducted at the Clinical Investigation Unit, 
Beaumont Hospital and was approved by the hospital 
Ethical Committee and by the National Drugs Advisory 
Board. All subjects gave written informed consent. 
Study Design Subjects remained on their normal diet 
on the days prior to study. Sodium status was assessed 
by a 24 h urine collection conducted the preceding day. 
On the morning of infusion they ate a modest breakfast, 
abstained from caffeinated beverages, and had ab-
stained from cigarette smoking since 21:00 the previous 
evening. At 09:00 subjects lay supine and an intrave-
nous cannula was sited in a forearm vein in each arm; 
one for infusion, the other for blood sampling. A control 
infusion of 5% dextrose was infused at 10 mL/h for 60 
min via an infusion pump (Braun perfusor, Germany). 
Blood pressure was measured at 3 min intervals by an 
indirect automated sphygmomanometer (Vitastat 900-
D). A cardiac monitor with visual display recorded heart 
rate throughout the study. 
At the end of the 60 min control period, basal blood 
samples were withdrawn for measurement of plasma 
ANG II, aldosterone, urea, electrolytes, and platelet 
ANG II receptor density. A graded infusion of ANG II 
[Asn1,Val5]ANG-(l-8)octapeptide (Hypertensin, Ciba 
Geigy Pharmaceuticals, Horsham, Sussex, England) in 
5% dextrose was commenced at 0.3, 1.0, 3.0, and 10 
ng/kg/min, each dose infused for 30 min. A blood 
sample was withdrawn at the end of each infusion pe-
riod for plasma ANG II and aldosterone. All blood sam-
ples were taken in prechilled tubes, immediately placed 
on ice, and centrifuged at 4°C. Plasma was removed, 
placed in prechilled cryotubes which were frozen in 
liquid nitrogen and stored at — 80 °C until assayed. 
Biochemical Measurements Plasma levels of endoge-
nous ANG II and Hypertensin were measured by modi-
fication of a previously described standard method. 1 5 
Blood samples were drawn as originally described on an 
inhibitor solution containing EDTA, o-phenanthroline 
and neomycin but no renin inhibitor.16 The original ex-
traction procedure yielded consistently > 95% recover-
ies of Hypertensin added to plasma in picomolar con-
centrations as used in the present infusion experiments. 
Overall recoveries (including HPLC) were also virtually 
complete ( > 9 0 % ) . Isocratic separation of the different 
ANG II peaks was obtained with 27% methanol in the 
mobile phase: the retention times being 4.3 min and 9.9 
min for Hypertensin and endogenous ANG II respec-
tively. Cross-reaction of the ANG II antiserum with Hy-
pertensin was 56%. Total immunoreactive ANG II was 
measured with a monoclonal antibody which we had 
produced by the somatic cell fusion technique1 7 and 
exogenous cross-reacting (13.6%) Hypertensin was 
subtracted to obtain endogenous immunoreactive ANG 
II (ir-ANG II). This was done to investigate, by a differ-
ent method, the feedback suppression of the renin an-
giotensin system during Hypertensin infusion. Ir-ANG 
II is the sum of true ANG II and all the cross-reacting 
angiotensin peptides.1 8 No angiotensin peptide cross-
reacted more than 105% (ANG III). 1 7 
Platelet ANG II receptor density and affinity were 
measured as previously described19 using a modifica-
tion of the method described by Mann and colleagues.20 
Plasma aldosterone was measured by radioimmunoas-
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TABLE 1 . BASELINE CLINICAL AND BIOCHEMICAL CHARACTERISTICS OF YOUNG AND ELDERLY GROUPS 
Young Elderly 
Age, years 27.5 (25.3-29.7) 59.6 (57.1-62.1) 
Weight, kg 69.6 (59.4-79.8) 76.3 (65.1-87.5) 
Heart rate, beats/min 63.9 (54.8-73.0) 59.2 (52.9-65.5) 
Blood pressure, mm Hg 
Systolic 113.8 (106-121) 115.6(110-122) 
Diastolic 66.0 (58.6-73.4) 81.5 (75.6-87.4)* 
Mean 81.7(76.3-87.1) 92.9 (88.2-97.6)* 
Platelet ANG II receptor 
Density, fmol/109 cells 1.14 (0.21-2.07) [7] 6.5 (1.9-11.l)t [7] 
Affinity, [Kd] pmol/L 66.7 (32.5-101) [7] 81.2 (55.7-107) [7] 
Plasma ANG II, fmol/mL 3.7(1.2-6.2) 3.4 (0-7.7) [4] 
Plasma aldosterone, pg/mL 50.4 (42.3-58.5) 55.9 (29.4-82.4) 
Urinary sodium, mmol/24 h 153 (111-194) 175 (113-237) 
Urinary potassium, mmol/24 h 78.1 (47.9-108) 82.2 (48.8-116) 
Serum sodium, mmol/L 141 (140-142) 140 (138-142) 
Serum potassium, mmol/L 4.5 (4.2-4.8) 4.3 (4.1-4.5) 
Mean (95% confidence limits), * Ρ < .001, -j- Ρ < .01, elderly compared to young, n = 8 unless otherwise indicated in square brackets. 
say. 2 1 Plasma and urinary electrolytes were measured 
by standard automated methods. 
Blood Pressure and Heart Rate Responses To allow 
time for plasma ANG II levels to reach steady state, 2 2 
blood pressure and heart rate readings recorded during 
the first 10 min following a change in infusion dose were 
not included in the analysis. 
Statistical Analysis All results are expressed as means 
with 95% confidence limits. Student's unpaired t test 
was used to examine differences in basal values be­
tween the two age groups. Two factor analyses of var­
iance (ANOVA) with repeated measures on the time 
factor were used to examine the changes in response to 
ANG II infusion. Normal distributions were assumed 
for most variables; where skewed distributions were 
identified, natural logarithms were used to convert the 
data to normal. All analyses were carried out using the 
raw or logarithmic data, but some findings have been 
expressed as percentage changes in mean values to 
highlight important group differences. Statistical signif­
icance was taken at the conventional 5% level. 
RESULTS 
Baseline clinical, hormonal, and receptor characteristics 
of both groups are shown in Table 1. Young and old 
groups did not differ significantly in their mean body 
weight, serum or urinary electrolytes, basal heart rate, 
systolic blood pressure, or basal plasma aldosterone. 
The 24 h urinary sodium did not influence basal hor­
mone levels in either group. Baseline diastolic and mean 
arterial pressures as well as platelet ANG II receptor 
density were significantly higher in old than young. 
There was a negative correlation between platelet ANG 
II receptor density and the increase in aldosterone in 
response to Hypertensin infusion (r = — 0.61, Ρ = .035) 
and a positive correlation with the increase in systolic 
blood pressure although this failed to reach statistical 
significance (r = 0.51, Ρ = .065). 
Hypertensin infusion resulted in significant increases 
in plasma Hypertensin levels in both groups (P < .001, 
Figure 1, upper panel). The increases in plasma Hyper­
tensin level did not differ significantly between the 
young and old subjects (P = .669). Mean (95% confi­
dence limits) baseline endogenous ANG II level was 
marginally, but not significantly, lower in the old group 
than in the young group [3.4 ( < 0 . 1 to 7.7) ν 3.7 (1.2 to 
6.2), fmol/mL, respectively]. These were suppressed 
significantly (P < .001) to 0.9 (0 to 3.1) and 2.1 (0.6 to 
3.7) respectively by the infusion of Hypertensin at a rate 
of 3 ng/kg/min; similar levels of suppression were ob­
served at an infusion rate of 10 ng/kg/min (Figure 1, 
middle panel). Mean endogenous ANG II levels were 
lower in the old throughout the Hypertensin infusion 
but the differences between the groups were not statis­
tically significant (P = .775). A similar decrease in en­
dogenous ir-ANG II was found during Hypertensin 
infusion when cross-reacting (and specifically quanti-
tated) Hypertensin levels were subtracted from total ir-
ANG II which was measured directly (without HPLC) 
with monoclonal antibodies. Again, however, there was 
no difference between the age groups (P = .486; Figure 
1, lower panel). 
Systolic (SBP), diastolic (DBP), and mean arterial 
(MAP) pressures all increased significantly in both 
groups in response to Hypertensin infusion (Figure 2). 
The increase in SBP relative to baseline was significantly 
greater in the old than in the young subjects at infusion 
rates of 1 (P < .05), 3 (P < .01) and 10 (P < .001) ng/ 
kg/min. The increments in DBP and MAP during Hy-
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FIGURE 1. (upper panel) Hypertensin ([Asn1, Val5] angioten­
sin II), (middle panel) endogenous ANG II ([Asp^Ile5] angioten­
sin II), and (lower panel) immunoreactive endogenous ANG II 
plasma levels during Hypertensin infusion in young and old 
healthy subjects, mean ± SEM, # Ρ < .05, # # Ρ < .01, # # # Ρ < 
.001, ν baseline. Decreasing concentrations of endogenous ANG II 
(middle and lower panels) indicate feedback suppression of 
renin by infused Hypertensin. Immunoreactive ANG II was ob­
tained by conventional radioimmunological measurement using 
monoclonal antibodies but without prior HPLC. Immunoreactive 
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[ A s n 1 , V a l 5 ] angiotensin II, ng/kg/min 
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FIGURE 2. SBP, DBP and MAP response to Hypertensin 
([Asrf^al5] angiotensin II) infusion in young and old, mean ± 
SEM. * Ρ < .05, ** Ρ < .01, *** Ρ < .001, old compared to young; 
# # Ρ < .01, # # # Ρ < .001, ν baseline. 
pertensin infusion did not differ significantly between 
the two groups. Heart rate fell during infusion in the 
young group with a significant difference from basal at 
the 10 ng/kg/min infusion rate (P < .05, Figure 3). 
There was a minimal and not significant decline in heart 
rate in the older subjects. When the change in heart rate 
was expressed as a percentage of basal heart rate there 
was a significant difference in response between young 
and old groups at the 10 ng/kg/min infusion rate (P < 
.05) with a significantly blunted response in the old. 
Hypertensin infusion resulted in significant increases 
in plasma aldosterone in both groups (Figure 4). The 
increment in plasma aldosterone was greater in the 
young than in the old subjects at infusion rates of 1, 3, 
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FIGURE 3. Heart rate response to Hypertensin ([Asrf^al5] an­
giotensin II) infusion in young and old, mean ± SEM, # Ρ < .05 ν 
baseline. 
and 10 ng/kg/min (all Ρ < .001). Relative to the base­
line levels, the absolute increases observed were on 
average 2 to 3 times greater in the young than in the old 
at these infusion rates. There was a significant negative 
correlation between 24 h urinary sodium and the aldos­
terone response to Hypertensin infusion for the young 
group (r = —0.88, Ρ = .01) but not for the old group 
(r = —0.61, Ρ = .14) or the two groups combined (r = 
- 0 . 4 9 , Ρ = . 0 8 ) . 
DISCUSSION 
The present study documents the effect of age on blood 
pressure, heart rate, endogenous ANG II and aldoster­
one responses to Hypertensin infusion. It is the first 
study to measure both endogenous and exogenous (Hy­
pertensin) plasma ANG II levels attained during Hyper­
tensin infusion. Hypertensin has been used for several 
decades for "angiotensin II" infusions. It appears bio­
logically equipotent to true ANG II despite the small 
differences in the molecular structure [Asn1,Val5 instead 
of AspMle5 sequence]. Conversion of Hypertensin into 
true human ANG II in vivo has never been observed and 
is very unlikely. Antisera differ if they are obtained in 
rabbits immunized with these two peptides and full 
cross-reaction is rare. 2 3 , 2 4 Similar plasma Hypertensin 
levels were found in both young and old groups during 
infusion and mean endogenous ANG II was lower in the 
elderly throughout the Hypertensin infusion although 
the difference was not significant. The increment in sys­
tolic pressure was greater in old than young in response 
to infusion, however, diastolic and mean arterial pres­
sure responses were similar in both groups. Platelet 
ANG II receptor density was greater in old subjects. In 
contrast to pressor responsiveness, aldosterone respon­
siveness was markedly reduced in the old at all infusion 
rates except the initial low dose infusion. 
In this study we have shown that it is possible to 
measure specifically and simultaneously exogenous and 
endogenous ANG II in plasma during Hypertensin in­
fusion. We have demonstrated for the first time that 
endogenous ANG II concentrations decrease dose de­
pendency with increasing levels of Hypertensin in both 
young and old healthy subjects. Even ir-ANG II (which 
is the sum of true ANG II and all the cross-reacting 
angiotensin peptides of conventional radioimmunoas­
says 1 8) decreased during Hypertensin infusion (Figure 
1) and thus also reflected the renin suppression induced 
by the infusion of Hypertensin. Unlike earlier investiga­
tions into the rate of angiotensin formation and meta­
bolic clearance, we can now directly and accurately 
quantitate ANG II itself (both the generated endoge­
nous ANG II and the accumulated infused Hypertensin) 
and we need no longer depend on the indirect evidence 
of plasma renin measurements. 
There is the possibility, not addressed in previous 
studies, 1 3 , 1 4 , 2 5 that age related changes in ANG II metab­
olism or clearance could give rise to differing levels of 
ANG II during infusion and account for differences in 
blood pressure or aldosterone responsiveness. In the 
present study, Hypertensin levels attained during infu­
sion were similar in both groups and only marginally, 
and not significantly, higher in the old at the highest 
infusion rate. Endogenous ANG II levels, however, 
were consistently, although not significantly, lower in 
the older group throughout the Hypertensin infusion. 
Interpretation of previous studies of pressor respon­
siveness to Hypertensin infusion in the elderly is com­
plicated by the lack of information on screening of el-
400 ι 
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[Asn 1 , V a l 5 ] angiotensin II, ng/kg/min 
infusion 
FIGURE 4. Aldosterone response to Hypertensin ([Asrf^al5] 
angiotensin II) infusion in young and old, mean ± SEM, *** Ρ < 
.001, young compared to old; # Ρ < .05, # # Ρ < .01, # # # Ρ < 
.001, ν baseline. 
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derly subjects to exclude disease 1 4 , 2 5 and salt depletion 
of subjects.1 4 Furthermore, since plasma ANG II levels 
attained during infusion have not been monitored, 1 3 ' 1 4 , 2 5 
a dose response relationship between pressor response 
and ANG II level cannot be assumed. In salt restricted 
subjects, greater increases in MAP have been observed 
in old than young in response to Hypertensin infusion.14 
The data are difficult to compare with ours since our 
subjects were not salt restricted and furthermore, in that 
study, data are provided on MAP alone with no infor-
mation on systolic responsiveness. In another investiga-
tion, less Hypertensin was required in elderly than 
young to raise DBP by 20 mm Hg. 2 5 Although these two 
studies suggest increased pressor sensitivity to ANG II 
in the old, in the present investigation we observed an 
age related difference in systolic rather than diastolic 
responsiveness. Those who have found an enhanced 
blood pressure response to Hypertensin in the elderly 
have attributed it to the age related decline in plasma 
renin. 1 4 , 2 5 A possible explanation for their findings 
would be an increase in vascular smooth muscle ANG II 
receptor density with age. In the present and a previous 
study, 1 9 we have found platelet ANG II receptor density 
to be increased in the old and there was a positive, 
although not significant, correlation between receptor 
density and systolic blood pressure response to Hyper-
tensin. If increased platelet receptor density reflects that 
of vascular smooth muscle, it provides a possible expla-
nation for the increased systolic blood pressure re-
sponse, however, this would not explain why diastolic 
pressure response was not also increased. The greater 
systolic response may simply reflect a nonspecific 
mechanism such as reduced vascular compliance or in-
creased vascular stiffness in the older group. Alterna-
tively, it may reflect the decline in baroreceptor sensitiv-
ity which occurs with age. 2 6 The significantly blunted 
fall in heart rate during Hypertensin infusion in the old 
subjects is consistent with a decline in baroreceptor sen-
sitivity with age. This is complicated, however, by the 
fact that baroreceptor sensitivity is altered during Hy-
pertensin infusion. 2 7 , 2 8 In addition, infusion of Hyper-
tensin, at least at very high doses, also exerts effects on 
the sympathetic nervous system 2 9 " 3 2 and on the myo-
cardium, 3 3 , 3 4 thus, different responses with age at these 
sites cannot be excluded. 
The age related fall in supine and ambulant plasma 
aldosterone is well established 4 , 6 , 7 , 3 5 but the etiology is 
less clear. We have documented a severely impaired 
aldosterone response to Hypertensin in the older sub-
jects, despite similar plasma Hypertensin levels. The 
blunted response occurred at all but the lowest infusion 
rate. In this context, it may be of interest that we also 
found a negative correlation between platelet ANG II 
receptor density and the aldosterone response to Hy-
pertensin. As discussed earlier, there were methodolog-
ical problems with previous studies including a lack of 
plasma ANG II measurements, 1 3 , 1 4 , 3 6 however, a signifi-
cantly blunted aldosterone response to Hypertensin in 
the elderly was documented. 1 4 , 3 6 In another study, the 
aldosterone response to corticotropin (ACTH) was un-
changed but the response to both Hypertensin and po-
tassium was diminished in the elderly13 suggesting a 
generalized decline in aldosterone secretory response 
rather than a specific ANG II receptor defect. Different 
doses of Hypertensin may have been infused in young 
and elderly, however, since the investigators infused 
sufficient ANG II "to increase diastolic blood pressure 
by 20 mm Hg for an hour . " 1 3 In other studies, the al-
dosterone response to ACTH was either unchanged 1 4 or 
reduced 3 7 in the elderly. The aldosterone response to 
ANG II, potassium, and ACTH in suspensions of bovine 
adrenal zona glomerulosa cells is lower in cells from 
older animals.3 8 The reduced response to ANG II oc-
curred despite similar zona glomerulosa ANG II recep-
tor density in cells from young and old animals. Overall, 
therefore, the age related reduction in aldosterone re-
sponse to Hypertensin appears to be part of a general-
ized reduction in aldosterone biosynthesis or secretory 
response with age. 
In conclusion, Hypertensin infusion resulted in simi-
lar plasma Hypertensin levels in both young and old 
and a dose dependent decline in endogenous ANG II. 
Systolic rather than diastolic pressure response was in-
creased in the elderly and the heart rate response was 
attenuated which may reflect diminished baroreceptor 
sensitivity with age. Aldosterone response to Hyperten-
sin infusion was markedly blunted in the old. 
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